Following China, the U.S. will also begin clinical trials of Redsiewe for the treatment of new coronavirus pneumonia. On February 25th CNBC reported that the U.S. is planning a clinical trial of Gilead’s drug, Remdesivir, according to cNBC.
The trial, conducted jointly by the University of Nebraska Medical Center and the National Institute of Allergy and Infectious Diseases, will be conducted in up to 50 locations around the world and will be under agreement. The drug, called ridsiwee, was tested with a placebo.
By the time the website released the news on February 22nd local time, the trial had not begun recruiting patients.
“We think there’s only one drug that might have a real effect, and that’s Ridsie, ” Bruce Aylward, assistant director-general of the World Health Organization,” said CNN reported. “
However, Aylward also noted that registration rates are low because of declining patient numbers and trials of other drugs.
Redsywe, an experimental antiviral drug being developed by Gilead, has shown some hope of fighting other coronaviruses that cause SARS and MERS, having previously completed Phase II clinical trials overseas, but has not yet been tested in human coronaviruses. Since the outbreak, some studies have found that the drug has potential to treat new coronary pneumonia, so a clinical phase III trial is being conducted in China for patients with new coronary pneumonia.
In a statement sent to the journalists, Gilead said the two trials were being conducted in several hospitals in Hubei province, with patients in the process. Clinical trials are coordinated by the Sino-Japanese Friendship Hospital. Patients will receive a 10-day Reedsiwe intravenous injection. The main endpoints of the two studies included an improvement in clinical symptoms 28 days after treatment. Gilead is expected to get results in April.
“We must begin to prioritize projects that could save lives and save lives faster. “This is a global problem, not a Chinese problem, but a global problem, ” Mr. Aylward said at the launch. “
Gilead’s shares rose 4.6 per cent on February 24 local time, but fell more than 1 per cent in early trading the following day. The stock has a market capitalisation of about $92 billion, up nearly 11 percent over the past year.